Our look is new. Our purpose is the same. Learn more about our brand evolution.
Our look is new. Our purpose is the same. Learn more about our brand evolution.
For the past 25 years, countless researchers have dedicated their time and energy striving to find a cure for FSHD. Thanks to the work of researchers like Dr. Jeffrey Statland, Dr. Rabi Tawil and Peter Jones, PhD (just to name a few!), we are a strong community filled with some of the brightest minds in science.
At this year’s Patient Connect Conference on November 11, we want to open the floor for you to ask researchers your questions. Do you want to know what they’re working on? What the next big breakthrough may be? Now is your chance. Please send your questions to Beth.Johnston@fshdsociety.org, or share them on Twitter, Facebook and Instagram by using the hashtag #AskTheResearcher – – no later than November 8th!
We’ll present your questions to the researchers during the Q&A session at the Patient Connect Conference. We’ll also be sharing the questions and answers on the FSH Society website and our social media channels after the event.
I am from Argentina. I would like to know about the drug aTyr Pharma senior management will provide a Physiocrine-based therapeutics overview and present the previously disclosed first clinical data for its Resolaris™ program for the treatment of facioscapulohumeral muscular dystrophy (FSHD),..what they’re working on for cure the FSHD. Thanks a lot